CoagulationDisorders near Pompton Plains, NJ

Biography: Dr. Emond is the Vice Chairman of Surgery at Columbia University. He has over 30 years of experience performing liver transplantation and complex liver and biliary surgery in children and adults, including the first living donor liver transplantation (LDLT) in the United States. Dr. Emond has published extensively in this field and was the co-chair of the NIH A2ALL program for 13 years. In collaboration with the department of Medicine at Columbia, Dr. Emond recruited the leadership of the Columbia Center for Translational immunology that created the foundation for translational and clinical research in transplantation tolerance. This will lead the way to inducing transplant tolerance in liver patients with the mixed chimerism strategy. As Director of Transplantation at the Columbia University Medical Center Dr. Emond's activities foster clinical excellence and research across all 11 of the solid organ transplant programs at the Medical Center. In recognition of his national and international leadership in transplantation, Dr. Emond is the past president of the American Society of Transplant Surgeons, the pre-eminent association of a transplant surgery. Contribution to Science Living donor liver transplantation Dr. Emond has spent a substantial portion of his career developing living donor liver transplantation and studying the safety of the procedure in both the donor and recipient. He participated in the first living donor liver transplant in the United States and focused on refining the techniques of performing living donor liver transplants and split liver transplants. He was the national co-chair of the NIH-sponsored Adult-to-Adult Living Donor Liver Transplantation (A2ALL) consortium from 2002 to 2015 to study the safety and outcomes of living donor liver transplants. Hepatic resection/ischemia Dr. Emond developed techniques for surgical resection of liver tumors and studied the effect of ischemia during resection on postoperative liver function. These studies include the outcomes of the extent of hepatectomy, the biochemical response to major hepatectomy and ischemia-reperfusion injury of the liver in rodent models. He has studied the clinical safety of inducing total vascular exclusion to provide a bloodless field during the liver transection. This has applications in both liver cancer and living donor hepatectomies. Hepatocellular carcinoma treatment Dr. Emond has studied many aspects of managing patients with hepatocellular carcinoma. These studies have included characterizing the risk factors for recurrence of disease following transplantation due to comorbidities and tumor characteristics. The research team has also studied the optimal method of preventing tumor growth in patients with HCC on the liver transplant wait list in addition to optimal strategies of liver allocation to optimize outcomes following liver transplantation. These studies have contributed to proposed changes in UNOS exception point allocation for liver transplant candidates with HCC. Pediatric liver transplantation Dr. Emond helped develop the field of pediatric liver transplantation. Contributions to this field include: the use of living donors for pediatric patients; use of auxiliary liver transplants for metabolic diseases; use of partial liver grafts for pediatric patients; and technical modifications that improved outcomes for this patient population. Visit The Center for Liver Disease and Transplantation at columbiasurgery.org/liver

Biography: Dr. Lisa Roth is an Assistant Professor in the Departments of Pediatrics and Medicine at Weill Cornell Medicine. She is also the Director of the Adolescent and Young Adult Lymphoma Program at Weill Cornell Medicine/New York Presbyterian Hospital. Dr. Roth has been named the Charles, Lillian, and Betty Neuwirth Clinical Scholar in Pediatric Oncology. Dr. Roth completed her undergraduate work at Duke University. She received her medical degree from New York University School of Medicine. Dr. Roth conducted her residency at NewYork-Presbyterian/Weill Cornell and her fellowship in pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center and NewYork-Presbyterian where she served as chief fellow. Dr. Roth specializes in treating children, adolescents and young adults with lymphoma and leukemia. She is a member of the Children's Oncology Group and an active participant in Hodgkin lymphoma and non-Hodgkin lymphoma clinical trials. She is also a member of the Weill Cornell Center for Lymphoma, a group which is internationally recognized for it's leadership in the treatment of patients with lymphoma. Dr. Roth's research focuses on identifying new treatments for children with lymphoma. She is particularly interested identifying novel targeted therapies. Targeted therapies may be less toxic than conventional chemotherapy and may be able to rescue those patients with chemotherapy-resistant disease. Dr. Roth has been recognized for her work with awards from the National Institutes of Health (NIH), the Lymphoma Research Foundation, Hyundai Hope on Wheels Foundation, and the St. Baldrick's Foundation. For More Videos, please see below: OR-Live: Treating AYA Patients with Hodgkins Lymphoma (5/10/2017)https://www.youtube.com/watch?v=PT-Qwg2EvqgLymphoma Cancer Treatment NY - Weill Cornell Dr. Roth In the News: Taking Away the Toll (12/2015)http://www.nyrr.org/races-and-events/2016/nyrr-new-york-mini-10k/lisa-roth

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person

Care Philosophy: Dr. Phillips embraces the multi-disciplinary approach to cancer care at Cooperman Barnabas Medical Center. She works collaboratively with the members of the oncology team to ensure access to state of the art treatments and optimal patient outcomes.

Biography: Dr. Lyndon Kim, MD is a Hematology Specialist who practices in New York, NY. He is 71 years old and has been practicing for 40 years. Dr. Lyndon Kim, MD is affiliated with Mount Sinai Morningside and Mount Sinai Hospital.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Anna Pavlick, BSN, MSc, DO, MBA is a medical oncologist with over 20 years of experience treating patients with skin cancer, including melanoma, basal cell cancer,squamous cell cancer and Merkel cell carcinoma. She is also an expert in treating ocular melanoma, eyelid tumors and other rare solid tumor malignancies, including a research interest in neurofibromatosis-1 (NF1) malignancies. She is currently accepting new patients for both in-office visits and telehealth appointments.Dr. Pavlick was recruited to Weill Cornell Medicine as Professor of Medicine in the Division of Hematology & Medical Oncology. She is the founding Director of the Cutaneous Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian. Dr. Pavlick's major research interests include investigating targeted therapies, combination therapies and immunotherapies. She also conducts outcomes research evaluating quality of life.Dr. Pavlick earned her medical degree from the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School; her Master of Science in Human Anatomy from Fairleigh Dickinson University; and her Bachelor of Science in Biology and Nursing degree from Fairfield University. She completed an internal medicine residency at UMDNJ and hematology and oncology fellowship training at Memorial Sloan Kettering Cancer Center. In addition to her undergraduate and medical training, Dr. Pavlick graduated from the Drexel School of Medicine Executive Leadership in Academic Medicine in 2012 and earned her Master of Business Administration (MBA) degree from Columbia University Business School in 2017.Dr. Pavlick has authored and co-authored over 100 publications and presented her research at international meetings. She serves on the several editorial boards, including The Journal of Drugs in Dermatology and The Journal of ImmunoTherapeutics of Cancer (Associate Editor). She is a member of leading oncology societies including American Society of Clinical Oncology (ASCO), American Academy of Clinical Research (AACR), the Society for Melanoma Research, Society for Immunotherapy and Translational Research in Cancer and the European Society of Medical Oncology (ESMO).